Signature Panel of 11 Methylated mRNAs and 3 Methylated lncRNAs for Prediction of Recurrence-Free Survival in Prostate Cancer Patients

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Cao L, Yang Z, Qi L, Chen M. Robot-assisted and laparoscopic vs open radical prostatectomy in clinically localized prostate cancer: perioperative, functional, and oncological outcomes: a Systematic review and meta-analysis. Medicine. 2019;98(22):e15770. doi:10.1097/MD.0000000000015770
   PubMed Web of Science ®Google Scholar
• Hackman G, Taari K, Tammela TL, et al. Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension. Eur Urol. 2019;76(5):586–595. doi:10.1016/j.eururo.2019.07.001
   PubMed Web of Science ®Google Scholar
• Barbas Bernardos G, Herranz Amo F, González San Segundo C, et al. Survival analysis of patients with prostate cancer and unfavorable risk factors treated with radical prostatectomy and salvage radiotherapy after biochemical recurrence and persistence. Actas Urol Esp. 2020;44(10):701–707. doi:10.1016/j.acuro.2020.02.001
   Web of Science ®Google Scholar
• Zattoni F, Morlacco A, Matrone F, et al. Multimodal treatment for high-risk locally-advanced prostate cancer following radical prostatectomy and extended lymphadenectomy. Minerva Urol Nefrol. 2019;71(5):508–515. doi:10.23736/S0393-2249.19.03388-5
   Web of Science ®Google Scholar
• Hashimoto T, Ohori M, Shimodaira K, et al. Prostate-specific antigen screening impacts on biochemical recurrence in patients with clinically localized prostate cancer. Int J Urol. 2018;25(6):561–567. doi:10.1111/iju.13563
   Web of Science ®Google Scholar
• Abdel Raheem A, Chang KD, Alenzi MJ, et al. Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: analysis of 359 cases with a median follow-up period of 26 months. Int J Urol. 2018;25(12):1006–1014. doi:10.1111/iju.13808
   PubMed Web of Science ®Google Scholar
• Tollefson MK, Karnes RJ, Rangel LJ, Bergstralh EJ, Boorjian SA. The impact of clinical stage on prostate cancer survival following radical prostatectomy. J Urol. 2013;189(5):1707–1712. doi:10.1016/j.juro.2012.11.065
   Web of Science ®Google Scholar
• Mithal P, Howard LE, Aronson WJ, et al. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from shared equal access regional cancer Hospital database. Int J Urol. 2015;22(4):362–366. doi:10.1111/iju.12704
   Web of Science ®Google Scholar
• Gandaglia G, Briganti A, Clarke N, et al. Adjuvant and salvage radiotherapy after radical prostatectomy in prostate cancer patients. Eur Urol. 2017;72(5):689–709. doi:10.1016/j.eururo.2017.01.039
   PubMed Web of Science ®Google Scholar
• Sugiura M, Sato H, Kanesaka M, et al. Epigenetic modifications in prostate cancer. Int J Urol. 2020;28(2):140–149. doi:10.1111/iju.14406
   Web of Science ®Google Scholar
• Liao Y, Xu K. Epigenetic regulation of prostate cancer: the theories and the clinical implications. Asian J Androl. 2019;21(3):279–290. doi:10.4103/aja.aja_53_18
   PubMed Web of Science ®Google Scholar
• Nowacka-Zawisza M, Wiśnik E. DNA methylation and histone modifications as epigenetic regulation in prostate cancer (Review). Oncol Rep. 2017;38(5):2587–2596. doi:10.3892/or.2017.5972
   Web of Science ®Google Scholar
• Wang L, Xie PG, Lin YL, Ma JG, Li WP. Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy. Med Sci Monit. 2014;20:1363–1368. doi:10.12659/MSM.891241
   Web of Science ®Google Scholar
• Lin YL, Xie PG, Wang L, Ma JG. Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy. Med Sci Monit. 2014;20:1376–1382. doi:10.12659/MSM.891247
   PubMed Web of Science ®Google Scholar
• Jiang Q, Xie M, He M, et al. PITX2 methylation: a novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancer. Medicine. 2019;98(1):e13820. doi:10.1097/MD.0000000000013820
   Web of Science ®Google Scholar
• Xu J, Tsai CW, Chang WS, et al. Methylation of global DNA repeat LINE-1 and subtelomeric DNA repeats D4Z4 in leukocytes is associated with biochemical recurrence in African American prostate cancer patients. Carcinogenesis. 2019;40(9):1055–1060. doi:10.1093/carcin/bgz061
   Web of Science ®Google Scholar
• Stott-Miller M, Zhao S, Wright JL, et al. Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1331–1339. doi:10.1158/1055-9965.EPI-13-1000
   Web of Science ®Google Scholar
• Goltz D, Gevensleben H, Dietrich J, et al. Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncoimmunology. 2016;5(10):e1221555. doi:10.1080/2162402X.2016.1221555
   PubMed Web of Science ®Google Scholar
• Li X, Zhang W, Song J, Zhang X, Ran L, He Y. SLCO4C1 promoter methylation is a potential biomarker for prognosis associated with biochemical recurrence-free survival after radical prostatectomy. Clin Epigenetics. 2019;11(1):99. doi:10.1186/s13148-019-0693-2
   Web of Science ®Google Scholar
• Geybels MS, Wright JL, Bibikova M, et al. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy. Clin Epigenetics. 2016;8(1):97. doi:10.1186/s13148-016-0260-z
   Web of Science ®Google Scholar
• Liao LE, Hu DD, Zheng Y. A four-methylated lncRNAs-based prognostic signature for hepatocellular carcinoma. Genes (Basel). 2020;11(8):908. doi:10.3390/genes11080908
   Web of Science ®Google Scholar
• Zeng Z, Cheng J, Ye Q, et al. A 14-methylation-driven differentially expressed rna as a signature for overall survival prediction in patients with uterine corpus endometrial carcinoma. DNA Cell Biol. 2020;39(6):975–991. doi:10.1089/dna.2019.5313
   Web of Science ®Google Scholar
• Kobayashi Y, Absher DM, Gulzar ZG, et al. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res. 2011;21(7):1017–1027. doi:10.1101/gr.119487.110
   PubMed Web of Science ®Google Scholar
• Povey S, Lovering R, Bruford E, Wright M, Lush M, Wain H. The HUGO Gene Nomenclature Committee (HGNC). Hum Genet. 2001;109(6):678–680. doi:10.1007/s00439-001-0615-0
   Web of Science ®Google Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 2008;9(1):559. doi:10.1186/1471-2105-9-559
   PubMed Web of Science ®Google Scholar
• Langfelder P, Zhang B, Horvath S. Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R. Bioinformatics. 2008;24(5):719–720. doi:10.1093/bioinformatics/btm563
   PubMed Web of Science ®Google Scholar
• Langfelder P, Luo R, Oldham MC, Horvath S, Bourne PE. Is my network module preserved and reproducible? PLoS Comput Biol. 2011;7(1):e1001057. doi:10.1371/journal.pcbi.1001057
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007
   PubMed Web of Science ®Google Scholar
• Goeman JJ. L1 penalized estimation in the Cox proportional hazards model. Biom J. 2010;52(1):70–84. doi:10.1002/bimj.200900028
   PubMed Web of Science ®Google Scholar
• Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16(4):385–395. doi:10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3
   PubMed Web of Science ®Google Scholar
• Raudvere U, Kolberg L, Kuzmin I, et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019;47(W1):W191–w198. doi:10.1093/nar/gkz369
   PubMed Web of Science ®Google Scholar
• Sinnott JA, Peisch SF, Tyekucheva S, et al. Prognostic utility of a new mRNA expression signature of Gleason score. Clin Cancer Res. 2017;23(1):81–87. doi:10.1158/1078-0432.CCR-16-1245
   PubMed Web of Science ®Google Scholar
• Zhang J, Yao T, Lin Z, Gao Y. Aberrant methylation of MEG3 functions as a potential plasma-based biomarker for cervical cancer. Sci Rep. 2017;7(1):6271. doi:10.1038/s41598-017-06502-7
   PubMed Web of Science ®Google Scholar
• Gao Y, Huang P, Zhang J. Hypermethylation of MEG3 promoter correlates with inactivation of MEG3 and poor prognosis in patients with retinoblastoma. J Transl Med. 2017;15(1):268. doi:10.1186/s12967-017-1372-8
   Web of Science ®Google Scholar
• Li H, Wang P, Liu J, et al. Hypermethylation of lncRNA MEG3 impairs chemosensitivity of breast cancer cells. J Clin Lab Anal. 2020;34(9):e23369. doi:10.1002/jcla.23369
   Web of Science ®Google Scholar
• Rawłuszko-Wieczorek AA, Horst N, Horbacka K, et al. Effect of DNA methylation profile on OATP3A1 and OATP4A1 transcript levels in colorectal cancer. Biomed Pharmacother. 2015;74:233–242. doi:10.1016/j.biopha.2015.08.026
   PubMed Web of Science ®Google Scholar
• Barrow TM, Nakjang S, Lafta F, et al. Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia. Br J Cancer. 2021;124(2):474–483. doi:10.1038/s41416-020-01117-8
   Web of Science ®Google Scholar
• Kuo IY, Chang JM, Jiang SS, et al. Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients. Int J Med Sci. 2014;11(8):779–787. doi:10.7150/ijms.7405
   Web of Science ®Google Scholar
• Dong Z, Zhang A, Liu S, et al. Aberrant Methylation-Mediated Silencing of lncRNA MEG3 functions as a ceRNA in esophageal cancer. Mol Cancer Res. 2017;15(7):800–810. doi:10.1158/1541-7786.MCR-16-0385
   PubMed Web of Science ®Google Scholar
• Zhang J, Lin Z, Gao Y, Yao T. Downregulation of long noncoding RNA MEG3 is associated with poor prognosis and promoter hypermethylation in cervical cancer. J Exp Clin Cancer Res. 2017;36(1):5. doi:10.1186/s13046-016-0472-2
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yang H, Xia W, et al. LncRNA MEG3 inhibits the progression of prostate cancer by facilitating H3K27 trimethylation of EN2 through binding to EZH2. J Biochem. 2020;167(3):295–301. doi:10.1093/jb/mvz097
   PubMed Web of Science ®Google Scholar
• Luo Y, Kaz AM, Kanngurn S, et al. NTRK3 is a potential tumor suppressor gene commonly inactivated by epigenetic mechanisms in colorectal cancer. PLoS Genet. 2013;9(7):e1003552. doi:10.1371/journal.pgen.1003552
   Web of Science ®Google Scholar
• Li L, Lee KM, Han W, et al. Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer. Hum Mol Genet. 2010;19(21):4273–4277. doi:10.1093/hmg/ddq351
   PubMed Web of Science ®Google Scholar
• Tan F, Zhu H, Tao Y, et al. Neuron navigator 2 overexpression indicates poor prognosis of colorectal cancer and promotes invasion through the SSH1L/cofilin-1 pathway. J Exp Clin Cancer Res. 2015;34(1):117. doi:10.1186/s13046-015-0237-3
   Web of Science ®Google Scholar
• Jiang H, Gu J, Du J, Qi X, Qian C, Fei B. A 21‑gene support vector machine classifier and a 10‑gene risk score system constructed for patients with gastric cancer. Mol Med Rep. 2020;21(1):347–359. doi:10.3892/mmr.2019.10841
   Web of Science ®Google Scholar
• Piqué DG, Montagna C, Greally JM, Mar JC. A novel approach to modelling transcriptional heterogeneity identifies the oncogene candidate CBX2 in invasive breast carcinoma. Br J Cancer. 2019;120(7):746–753. doi:10.1038/s41416-019-0387-8
   PubMed Web of Science ®Google Scholar
• Clermont PL, Crea F, Chiang YT, et al. Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer. Clin Epigenetics. 2016;8(1):16. doi:10.1186/s13148-016-0182-9
   Web of Science ®Google Scholar
• Park SB, Hwang KT, Chung CK, Roy D, Yoo C. Causal Bayesian gene networks associated with bone, brain and lung metastasis of breast cancer. Clin Exp Metastasis. 2020;37(6):657–674. doi:10.1007/s10585-020-10060-0
   PubMed Web of Science ®Google Scholar
• Ding G, Xu X, Li D, et al. Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation. Cell Death Dis. 2020;11(10):893. doi:10.1038/s41419-020-03019-2
   Web of Science ®Google Scholar
• Xie W, Zhang J, Zhong P, et al. Expression and potential prognostic value of histone family gene signature in breast cancer. Exp Ther Med. 2019;18(6):4893–4903. doi:10.3892/etm.2019.8131
   PubMed Web of Science ®Google Scholar
• Hu R, Lu Z. Long non‑coding RNA HCP5 promotes prostate cancer cell proliferation by acting as the sponge of miR‑4656 to modulate CEMIP expression. Oncol Rep. 2020;43(1):328–336. doi:10.3892/or.2019.7404
   PubMed Web of Science ®Google Scholar
• Dong Y, Cai Y, Liu B, et al. HOXA13 is associated with unfavorable survival and acts as a novel oncogene in prostate carcinoma. Future Oncol. 2017;13(17):1505–1516. doi:10.2217/fon-2016-0522
   Web of Science ®Google Scholar
• Simpson MA, Wilson CM, McCarthy JB. Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am J Pathol. 2002;161(3):849–857. doi:10.1016/S0002-9440(10)64245-9
   Web of Science ®Google Scholar
• Lokeshwar VB, Lopez LE, Munoz D, et al. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res. 2010;70(7):2613–2623. doi:10.1158/0008-5472.CAN-09-3185
   Web of Science ®Google Scholar
• Wu M, Huang Y, Chen T, et al. LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis. J Cell Mol Med. 2019;23(1):29–38. doi:10.1111/jcmm.13658
   PubMed Web of Science ®Google Scholar
• Yegnasubramanian S, Wu Z, Haffner MC, et al. Chromosome-wide mapping of DNA methylation patterns in normal and malignant prostate cells reveals pervasive methylation of gene-associated and conserved intergenic sequences. BMC Genomics. 2011;12(1):313. doi:10.1186/1471-2164-12-313
   Web of Science ®Google Scholar